Epigenetic reprogramming in neurological diseases and chronic pain

Pathological pain disorders are a growing healthcare challenge; in 2016, approximately 20% of adults in the United States alone live with a form of chronic pain [1]. The majority of FDA-approved chronic pain treatments are not uniformly effective across patients, the therapeutic effectiveness of current treatments within responsive cohorts is variable, and opioids and related analgesics are addictive and subject to tolerance during treatment. New therapies have been developed to target specific types of chronic pain that have well-described origins. For example, the use of CGRP blocking antibodies to mitigate pain associated with migraine [2,3]. But for most forms of chronic pain non-addictive highly efficacious treatments are lacking and opioids, including morphine, continue to have widespread use in the treatment of neuropathic pain despite the high doses required for analgesia [4].

A common feature of chronic pain is long lasting, pathological changes in neuronal excitability, originating from disease-dependent, cell-type specific alterations in the expression and function of ion channels [5–7]. Identifying cell-specific processes that control ion channel gene expression is critical if we are to understand more fully how neuronal injury leads to long lasting dysregulation of ion channel expression and function. Dynamic changes in epigenetic marks in different neuron subtypes, during development, and in response to changes in activity and environment coordinate expression levels of functionally related genes, including those that encode ion channels [8–10]. But, persistent reprogramming of the epigenetic landscape can lead to abnormal changes in gene expression and this is a common feature of many neurological disorders including Alzheimer’s and Parkinson’s diseases [11,12] Huntington’s Disease, Amyotrophic Lateral Sclerosis [13], Autism Spectrum Disorders [14], Rett Syndrome [15] and chronic pain [16]. In most, if not all of these
diseases, prolonged alteration in epigenetic regulation impacts a large number of genomic loci which, as a consequence, results in chronically abnormal expression and actions of gene networks. There is strong interest in therapeutic approaches to reverse disease-associated changes in ion channel expression. Epigenetic-based therapies have proven effective in certain cancers and other diseases [17,18].

**Epigenetic signatures altered in chronic pain**

DNA methylation, histone modifications and chromatin remodeling are interconnected processes that depend on a complex set of factors that combine to form the epigenetic machinery. Epigenetic factors influence the complete range of molecular interactions that control gene expression and these in turn influence transcriptome compositions of different cell subtypes, at different stages of development, following changes in activity and more. It is increasingly evident that a reprogramming of the epigenetic landscape (DNA, histones, and chromatin) in affected cells is a feature of many diseases, including in neuropathic pain [16,19–21]. Moreover, epigenetic marks can be used to inform disease origin and treatment strategies [17,22].

In neuropathic pain, injured neurons exhibit altered histone modification patterns that impact protein access to gene loci [16,21,23] including transcription factor occupancy at gene promoter regions [21,24], and altered DNA methylation of gene promoters and alternatively spliced exons [19,25–27].

**Histone modifications**, principally acetylation, methylation, and phosphorylation, are essential elements involved in the dynamic control chromatin structure. These histone modifications are key for regulated, coordinated gene expression and RNA processing. For example, in affected dorsal root ganglia (DRG) after nerve injury, there is increased methylation of lysine 9 of the histone H3 complex (H3K9) via upregulation of the lysine methyltransferase G9a. Injury-induced accumulation of dimethylated H3K9 (H3K9me2) in gene promoter regions represses transcriptional activity of more than 600 genes [16,23]. Among these genes, Kcna4, Kcna2, Kcnd2, and Kcnq2 encode four different voltage-gated potassium ion channels that collectively function to curtail neuronal excitability. H3K9me2 within the promoter regions of these genes down regulates Kᵥ channel expression in affected DRG causing increased neuronal excitability and contributing to neuropathic pain pathology [16,23,28]. Such coordinated action over several functionally related gene loci illustrates the hierarchical position that epigenetic mechanisms exert in the dynamic control of neuronal excitability.

**DNA methylation** occurs primarily on cytosines followed by guanines (CpG) and specifically on the 5th carbon of the pyrimidine ring of cytosine (5-methylcytosine or 5mC). CpG methylation is catalyzed by DNA methyltransferases (DNMTs) of which DNMT3a and DNMT3b promote de novo methylation of CpG sites involved in dynamic control of gene expression. DNA demethylation oxidation is catalyzed by Ten Eleven Translocation (TET) enzymes (TET1, TET2, and TET3). TETs convert 5mC into 5-hydroxymethylcytosine (5hmC) [29]. A comparison of CpG methylation patterns in unaffected and affected DRG in peripheral nerve injury models shows alterations in ~15% of methylation loci [19]. CpG methylation across the genome is overall reduced across the genome of affected DRG neurons [19,27]. Dynamic CpG methylation regulates neuronal intrinsic membrane excitability and it has been implicated in neuropathic pain [30]. Therapeutic strategies that increase CpG methylation might be expected to alleviate or reverse some of pathophysiological changes associated with peripheral nerve injury. Interestingly, methyl donor-enriched diets have been reported to attenuate certain sensory pathologies associated with nerve injury in mice [31,32], although the mechanisms of action of methyl donor enriched diets remain to be established.

The majority of nerve injury-induced alterations in genome-wide CpG methylation patterns are located in intergenic regions (between genes) [19] which contain regulatory mechanisms that control gene expression. CpG methylation at the promoter region of the μ-opioid receptor gene, *Oprm1*, is increased in affected DRG following nerve injury. This hypermethylation of the *Oprm1* promoter impairs *Oprm1* RNA processing leading to
Cell-specific alternative splicing of CaV2.2 channels in heat-sensing nociceptors

CaV2.2 channels at presynaptic termini of nociceptors in the spinal cord dorsal horn regulate glutamate release and thus synaptic efficacy. As has been amply documented, CaV2.2 channel inhibitors alleviate intractable chronic pain in humans, as well as in various animal models of pain [37–40]. Ziconotide (Prialt®), opioids and gabapentinoids downregulate CaV2.2 channel activity in nociceptors by distinctly different mechanisms: occluding the ion pore of the CaV2.2 channel directly (ziconotide); interfering with channel gating via G-protein coupled receptor activation (morphine); or acting via the α2δ-1 protein to promote CaV2.2 channel internalization (gabapentin) [36,41]. Interestingly, the inhibitory efficacy of opioids on CaV2.2 channels via μ-opioid receptor activation differs between e37 C-termini splice isoforms of CaV2.2. As summarized in Figures 1 and 2, in heat-sensitive Trpv1 nociceptors, the e37a splice form of CaV2.2 is expressed and it is more strongly inhibited by μ-opioid receptor activation especially under conditions of prolonged excitation. By comparison, the more commonly expressed splice form of CaV2.2, e37b, dominates in most other neurons and it is less sensitive to μ-opioid receptor inhibition [25,35,42–46]. This difference in morphine efficacy, between CaV2.2 splice isoforms impacts behavior. The intrathecal analgesic effects of morphine in vivo [35] and, most relevant to this discussion, abnormal cell-specific splicing of CaV2.2 in heat-sensitive Trpv1 nociceptors following peripheral nerve injury, leads to reduced expression of the e37a splice isoform of CaV2.2 and an accompanying reduction in the analgesic efficacy of morphine [25,34,36].

Disease-associated changes in alternative splicing of CaV2.2 are likely to contribute to the reduced therapeutic efficacy of morphine in neuropathic pain [25,33,34,36,47–49]. Approaches to prevent or correct persistent changes in cell-specific alternative splicing of CaV2.2, and potentially other synaptic proteins, in affected nociceptors could prove beneficial and might improve morphine efficacy in the treatment of chronic pain.

Epigenetic mechanisms underlie cell-specific alternative splicing of CaV2.2 channels

Until recently, we knew virtually nothing of the factors that control cell-specific alternative splicing of ion channels in affected nociceptors in chronic pain models. This knowledge gap persists despite compelling and growing evidence for the critical importance of this process in normal and abnormal neuronal function [36,50–52]. This changed with our recent discovery that cell-specific epigenetic modification controls cell-specific alternative splicing of e37a in Cacna1b in Trpv1 sensitive nociceptors, and that nerve-injury triggers epigenetic reprogramming altering splicing and calcium ion channel function (Figures 1 and 2) [25]:

1. In most neurons and in non-Trpv1 DRG cells, five CpG sites in exon 37a of Cacna1b are strongly methylated and exon 37a methylation prevents binding of a CCCTC binding factor (CTCF) to its motif at this locus. CTCF is a ubiquitous DNA binding protein that has a wide range of functions [53]. By contrast, in Trpv1 nociceptors, the same five CpG sites in exon 37a of Cacna1b are unmethylated, or rarely methylated, allowing CTCF to bind to its motif in exon 37a of Cacna1b.

2. Exon 37a is defined by a weak splice junction; in most cells, the intron-exon 37a boundary is not recognized by the spliceosome, exon 37a is normally skipped during pre mRNA splicing, and the mutually exclusive exon 37b which is defined by a strong splice junction is included.

3. In Trpv1 nociceptors, CTCF binds exon 37a converting a weak splice junction to one that is now recognized by the spliceosome [54],
and exon 37a is now approximately as likely to be included as exon 37b. Because exons 37a and 37b are mutually exclusive when exon 37a is included, e37b is excluded.

(4) Days after peripheral nerve injury that leads to prolonged hyperalgesia, the hypomethylation state of exon 37a in Trpv1 nociceptors is disrupted; there is a persistent increase in exon 37a methylation, a decrease in exon 37a inclusion and as an accompanying increase in exon 37b inclusion in Trpv1 nociceptors ipsilateral to the injury.

(5) The persistent disruption in the normal hypomethylation state of exon 37a in Cacna1b in Trpv1 nociceptors is coupled to reduced inhibitory actions of μ-opioid receptor activation on Ca_v2.2 channels in affected neurons, and reduced intrathecal morphine analgesia in behavior.

Our findings raise a number of questions including is cell-specific, exon-specific CpG methylation a general mechanism controlling cell-specific alternative gene splicing of ion channels and other genes in nociceptors? Are DNA methyltransferases (DNMTs) normally restricted from e37a and do DNMTs gain access to this site after injury? Can abnormal CpG methylation of e37a be prevented or reversed to normalize certain aspects of chronic pain pathophysiology?

Is cell-specific epigenetic modulation a general mechanism to control gene splicing?

Genome-wide epigenetic analyses in animal models of chronic pain reveal consistent, associated changed in DNA methylation and altered expression of hundreds of genes in affected DRG [19,27,55,56] and genome-wide CTCF mapping studies suggest a role for CTCF in control of splicing [54,57,58]. Such studies highlight DNA methylation as a common mechanism controlling the expression of gene networks according to changes in neuronal excitation [56,59]. Dynamic cell-specific changes in gene expression likely play important roles in normal homeostatic and synaptic plasticity that drive transient protective alterations in behavioral responses to stimuli. But, persistent, reprogramming of DNA methylation across neuronal genes in affected DRG post nerve injury, parallel disease pathology associated with chronic pain [19,20]. The proteins most commonly implicated in altered DNA methylation patterns associated with chronic pain are the DNA methyltransferases DNMT3a and DNMT3b [25,26,56,60].

DNMT3a is implicated in hypermethylation of key gene loci in affected DRG neurons following peripheral nerve injury, and in methylation of gene loci involved in calcium ion channel splicing in DRG nociceptors [25,26,56,60]. Specifically, in injured DRG, DNMT3a facilitates methylation levels at the Oprm1 promoter region leading to gene silencing and, similarly at the promoter region of voltage-gated K_V channel Kcna2 gene via activation of the transcription factor octamer transcription factor 1 [26]. In addition, as we have reported, overexpression of DNMT3a in a DRG-derived cell line increases the methylation state of the Cacna1b e37a locus suppressing e37a inclusion during alternative splicing (Figure 2) [25]. Thus, DNA methylation at specific loci (gene promoters or alternatively spliced exons) of functionally related genes in sensory neurons increases in response to nerve injury. The ensuing alterations in gene expression and RNA processing impact protein function and alter neuronal excitability and behavior relevant to pathological changes associated with peripheral nerve injury-induced chronic pain.

Our studies of Trpv1 nociceptor-specific hypomethylation of the e37a locus illustrate the importance of subtype-specific analyses of methylation modifications within specific genes (Figure 1) [25]. Indeed, the cell-specificity of CpG methylation of Cacna1b e37a locus would not be resolved in analysis of unsorted DRG. Thus, it will be important to define the genes whose expression and splicing patterns are modified by DNMT3a within genetically and functionally defined subtypes of sensory neurons. Deep sequencing analyses of different subtypes of DRG neurons show substantial differences in their gene expression profiles and, where available, of splice patterns [55,61,62].
How does DNMT3a gain access to normally protected gene loci after nerve injury?

An as yet unresolved question of great importance is how, following nerve injury, DNMT3a promotes hypermethylation of normally hypomethylated regulatory loci in neuronal genes that contribute to disease pathology. The specificity of DNMT3a action at specific loci is not easily explained simply by an overall increase in DNMT3a levels, and it favors a model in which DNMT3a gains access to gene loci, that is normally excluded from, in affected nociceptors after injury. Indeed, following nerve injury, previously protected regions of the chromatin become accessible to several DNA binding proteins [21]. In support of this hypothesis, DNMT3a levels are upregulated and DNMT3a accessibility to uniquely hypomethylated gene loci is increased in affected DRG for days in peripheral nerve injury models [25,26,56]. For example, promoter regions of neuronal genes, including Oprm1, Opr1, and Kcnq2 become hypermethylated in affected, but not in unaffected DRG [26,56,63]. Resolving the mechanism that controls DNMT3a, and more broadly all DNMTs, accessibility will be an enormous step forward in elucidating the key factors that might be disrupted following injury and in disease.

In one of the few studies to address the critical question of how DNMT3a gains access to loci, normally not accessible, Miyanari and colleagues implicate promyelocytic leukemia (PML) bodies. PML nuclear bodies are membrane-less, spherical organelles \(0.1-1 \mu m\) in diameter. They form 3-dimensional nuclear structures that physical exclude DNMT3a from specific gene loci to maintain hypomethylated regulatory elements crucial for the dynamic control of cell function [64]. It will be interesting to know whether the integrity of PML bodies is disrupted after nerve injury allowing access of DNMT3a to previously protected loci.

An alternative, not mutually exclusive possibility is the possibility that there is injury-induced reduction in the action of demethylating ten-eleven translocases (e.g. TET1 and TET2) at key loci.
In our recent studies, we showed that localizing TET1 to the e37a locus in Cacna1b using dCas9 DNA targeting reduces CpG methylation and impacts e37a splicing in a DRG-neuroblastoma cell line [25]. While TETs and potentially other regulatory proteins could contribute to alterations in gene expression and splicing, active methylation by a DNMT would seem to be necessary to explain persistent hypermethylation of key CpG sites following nerve injury [65–68].

**Can abnormal methylation be prevented or corrected to effectively normalize certain aspects of chronic pain pathophysiology?**

Knowledge of cellular mechanisms that control gene expression should inform the development of effective therapies to treat chronic pain states. Therapies that reverse or normalize injury-induced epigenetic reprogramming in nociceptors, including CpG methylation, hold promise for normalizing protein activity and drug responsiveness in certain pain disorders. For example, preventing injury-induced DNMT3a CpG methylation of e37a in Cacna1b and at Oprm1, Oprk1, and Kcna2 promoters in nociceptors could maintain normal levels of neuronal excitability and morphine efficacy.

Informed by careful mechanistic studies, therapeutic tools have been developed to compensate for damaging consequences of aberrant alternative splicing [69–72]. DNA engineering technologies, such as CRISPR-Cas9, have been employed to correct pathogenic epigenetic remodeling in neurons that interfere with alternative splicing, by compensatory shifts in alternative splicing, away from nonfunctional, toward functional splice isoforms [73–75]. As discussed above for...
Cacna1b, TET1 fused to CRISPER-dCas9 allows selective targeting of loci for in vitro and in vivo uses [25,76]. We applied this strategy to demethylate CpG sites in e37a, increasing e37a expression in a DRG-derived cell line [25] which suggests that this strategy could be used in vivo to counter hypermethylation following nerve injury.

As we gain knowledge of cell-specific epigenetic control of gene expression and splicing in sensory neurons, we come closer to developing new approaches to prevent and reserve epigenetic reprogramming associated with chronic pain pathology. Identifying cell-specific epigenetic control mechanisms, in particular, will be essential for achieving efficacy and specificity of drug action.

**Conclusion**

Dynamic, cell-specific modulation of ion channel action through altered expression levels and altered alternative splicing is essential for neuronal plasticity, adaptation and homeostasis in neurons. Signature epigenetic reprogramming in subsets of neurons occurs during periods of excessive neuronal activity associated with nerve injury, environmental exposure to toxins, or ongoing chronic diseases. We have highlighted CpG DNA methylation as an example of injury-sensitive, nociceptor-specific epigenetic control of calcium ion channel splicing but we expect this mechanism will be found to regulate splicing of other functionally related ion channel genes. Knowledge of epigenetic mechanisms that regulate cell-specific ion channel gene expression and alternative splicing patterns will inform new therapeutic approaches to correct or to compensate for epigenetic reprogramming in chronic pain.

**Acknowledgments**

This work was funded by grants NS055251 (DL), Warren Alpert Fellowship Award (EJLS) and K99NS116123 (EJLS).

**Disclosure statement**

The authors have no conflicts of interest to declare.

**Funding**

This work was supported by the National Institutes of Health [NS055251]; National Institutes of Health [K99NS116123]; Warren Alpert Foundation.

**ORCID**

Diane Lipscombe http://orcid.org/0000-0002-7146-9119

**References**

[1] Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67:1001–1006.

[2] Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123–2132.

[3] Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–434.

[4] Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65:1–49.

[5] Lipscombe D, Andrade A. Calcium channel CaValpha (1) splice isoforms - Tissue specificity and drug action. Curr Mol Pharmacol. 2015;8:22–31.

[6] von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73:638–652.

[7] Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci. 2014;17:153–163.

[8] Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33 (Suppl):245–254.

[9] Ma DK, Jang MH, Guo JU, et al. Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. Science. 2009;323:1074–1077.

[10] Shulha HP, Cheung I, Guo Y, et al. Coordinated cell type-specific epigenetic remodeling in prefrontal cortex begins before birth and continues into early adulthood. PLoS Genet. 2013;9:e1003433.

[11] Corces MR, Shcherbina A, Kundu S, et al. Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer’s and Parkinson’s diseases. Nat Genet. 2020;52:1158–1168.

[12] Marshall LL, Kllinger BA, Ensink E, et al. Epigenomic analysis of Parkinson’s disease neurons identifies Tet2 loss as neuroprotective. Nat Neurosci. 2020;23:1203–1214.
[13] Beaver M, Bhatnagar A, Panikker P, et al. Disruption of Tip60 HAT mediated neural histone acetylation homeostasis is an early common event in neurodegenerative diseases. Sci Rep. 2020;10:18265.

[14] Ramaswami G, Won H, Gandal MJ, et al. Integrative genomics identifies a convergent molecular subtype that links epigenomic with transcriptomic differences in autism. Nat Commun. 2020;11:4873.

[15] Li CH, Coffey EL, Dall’Agnese A, et al. MeCP2 links heterochromatin condensates and neurodevelopmental disease. Nature. 2020;586:440–444.

[16] Laumet G, Garriga J, Chen SR, et al. G9a is essential for epigenetic silencing of K(+) channel genes in acute-to-chronic pain transition. Nat Neurosci. 2015;18:1746–1755.

[17] Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet. 2019;20:109–127.

[18] Xiong S, Feng Y, Cheng L. Cellular reprogramming as a therapeutic target in cancer. Trends Cell Biol. 2019;29:623–634.

[19] Garriga J, Laumet G, Chen SR, et al. Nerve injury-induced chronic pain is associated with persistent DNA methylation reprogramming in dorsal root ganglion. J Neurosci. 2018;38:6090–6101.

[20] Golzenleuchter M, Kanwar R, Zaibak M, et al. Plasticity of DNA methylation in a nerve injury model of pain. Epigenetics. 2015;10:200–212.

[21] Palmisano I, Danzi MC, Hutson TH, et al. Epigenomic signatures underpin the axonal regenerative ability of dorsal root ganglia sensory neurons. Nat Neurosci. 2019;22:1913–1924.

[22] Donlin LT, Park SH, Giannopoulou E, et al. Insights into rheumatic diseases from next-generation sequencing. Nat Rev Rheumatol. 2019;15:327–339.

[23] Liang L, Gu X, Zhao JY, et al. G9a participates in nerve injury-induced Kcnq2 downregulation in primary sensory neurons. Sci Rep. 2016;6:37704.

[24] Zhang J, Chen SR, Chen H, et al. RE1-silencing transcription factor controls the acute-to-chronic neuropathic pain transition and Chrm2 receptor gene expression in primary sensory neurons. J Biol Chem. 2018;293:19078–19091.

[25] Lopez Soto EJ, Lipscombe D. Cell-specific exon methylation and CTCF binding in neurons regulate calcium ion channel splicing and function. Elife. 2020;9:e54879.

[26] Sun L, Zhao JY, Gu X, et al. Nerve injury-induced epigenetic silencing of opioid receptors controlled by DNMT3a in primary afferent neurons. Pain. 2017;158:1153–1165.

[27] Weng YL, An R, Cassin J, et al. An intrinsic epigenetic barrier for functional axon regeneration. Neuron. 2017;94:337–346 e336.

[28] Zhao X, Tang Z, Zhang H, et al. A long noncoding RNA contributes to neuropathic pain by silencing Kcnq2 in primary afferent neurons. Nat Neurosci. 2013;16:1024–1031.

[29] Pan Z, Xue ZY, Li GF, et al. DNA hydroxymethylation by ten-eleven translocation methylcytosine dioxygenase 1 and 3 regulates nociceptive sensitization in a chronic inflammatory pain model. Anesthesiology. 2017;127:147–163.

[30] Meadows JP, Guzman-Karlsson MC, Phillips S, et al. Dynamic DNA methylation regulates neuronal intrinsic membrane excitability. Sci Signal. 2016;9:ra83.

[31] Gregoire S, Millecamps M, Naso L, et al. Therapeutic benefits of the methyl donor S-adenosylmethionine on nerve injury-induced mechanical hypersensitivity and cognitive impairment in mice. Pain. 2017;158:802–810.

[32] Iskandar BJ, Rizk E, Meier B, et al. Folate regulation of axonal regeneration in the rodent central nervous system through DNA methylation. J Clin Invest. 2010;120:1603–1616.

[33] Rashid MH, Inoue M, Toda K, et al. Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. J Pharmacol Exp Ther. 2004;309:380–387.

[34] Altier C, Dale CS, Kisilevsky AE, et al. Differential role of N-type calcium channel splice isoforms in pain. J Neurosci. 2007;27:6363–6373.

[35] Andrade A, Denome S, Jiang YQ, et al. Opioid inhibition of N-type Ca2+ channels and spinal analgesia couple to alternative splicing. Nat Neurosci. 2010;13:1249–1256.

[36] Jiang YQ, Andrade A, Lipscombe D. Spinal morphine but not ziconotide or gabapentin analgesia is affected by alternative splicing of voltage-gated calcium channel CaV2.2 pre-mRNA. Mol Pain. 2013;9:67.

[37] Bannister K, Kucharczyk M, Dickenson AH. Hopes for the future of pain control. Pain Ther. 2017;6:117–128.

[38] Bowersox S, Mandema J, Tarczy-Hornoch K, et al. Pharmacokinetics of SNX-111, a selective N-type calcium channel blocker, in rats and cynomolgus monkeys. Drug Metab Dispos. 1997;25:379–383.

[39] Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004;11:3029–3040.

[40] Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol. 1995;35:707–734.

[41] Nieto-Rostro M, Ramgoolam K, Pratt WS, et al. Ablation of alpha2delta-1 inhibits cell-surface trafficking of endogenous N-type calcium channels in the pain pathway in vivo. Proc Natl Acad Sci U S A. 2018;115:E12043–E12052.

[42] Bell TJ, Thaler C, Castiglioni AJ, et al. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron. 2004;41:127–138.

[43] Castiglioni AJ, Raino J, Lipscombe D. Alternative splicing in the C-terminus of CaV2.2 controls expression and gating of N-type calcium channels. J Physiol. 2006;576:119–134.
[44] Lopez Soto EJ, Raingo J. A118G Mu opioid receptor polymorphism increases inhibitory effects on CaV2.2 channels. Neurosci Lett. 2012;523:190–194.

[45] Macabung N, Dolphin AC. Alternative splicing in Ca (V)2.2 regulates neuronal trafficking via adaptor protein complex-1 adaptor protein motifs. J Neurosci. 2015;35:14636–14652.

[46] Raingo J, Castiglioni AJ, Lipscombe D. Alternative splicing controls G protein-dependent inhibition of N-type calcium channels in nociceptors. Nat Neurosci. 2007;10:285–92.

[47] Mayer DJ, Mao J, Holt J, et al. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci U S A. 1999;96:7731–7736.

[48] Ossipov MH, Lopez Y, Nichols ML, et al. The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci Lett. 1995;199:87–90.

[49] Zhang X, Bao L, Shi TJ, et al. Down-regulation of mu-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy. Neuroscience. 1998;82:223–240.

[50] Gandal MJ, Zhang P, Hadjimichael E, et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 2018;362(6420):eaat8127.

[51] Li Q, Lee JA, Black DL. Neuronal regulation of alternative pre-mRNA splicing. Nat Rev Neurosci. 2007;8:819–831.

[52] Lopez Soto EJ, Gandal MJ, Gonatopoulos-Pournatzis T, et al. Mechanisms of neuronal alternative splicing and strategies for therapeutic interventions. J Neurosci. 2019;39:8193–8199.

[53] Ong CT, Corces VG. CTCF: an architectural protein bridging genome topology and function. Nat Rev Genet. 2014;15:234–246.

[54] Shukla S, Kavak E, Gregory M, et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature. 2011;479:74–79.

[55] Renthal W, Tochitsky I, Yang L, et al. Transcriptional reprogramming of distinct peripheral sensory neuron subtypes after axonal injury. Neuron. 2020;108:128–144 e129.

[56] Zhao JY, Liang L, Gu X, et al. DNA methyltransferase DNMT3a contributes to neuropathic pain by repressing Kcna2 in primary afferent neurons. Nat Commun. 2017;8:14712.

[57] Aigle E, Bellora N, Allo M, et al. A chromatin code for alternative splicing involving a putative association between CTCF and HP1alpha proteins. BMC Biol. 2015;13:31.

[58] Ruiz-Velasco M, Kumar M, Lai MC, et al. CTCF-mediated chromatin loops between promoter and gene body regulate alternative splicing across individuals. Cell Syst. 2017;5:628–637 e626.

[59] Descalzi G, Ikegami D, Ushijima T, et al. Epigenetic mechanisms of chronic pain. Trends Neurosci. 2015;38:237–246.

[60] Pollen-Mays SL, Centeno MV, Apkarian AV, et al. Expression of DNA methyltransferases in adult dorsal root ganglia is cell-type specific and up regulated in a rodent model of neuropathic pain. Front Cell Neurosci. 2014;8:217.

[61] Sharma N, Flaherty K, Lezgiyeva K, et al. The emergence of transcriptional identity in somatosensory neurons. Nature. 2020;577:392–398.

[62] Zheng Y, Liu P, Bai L, et al. Deep sequencing of somatosensory neurons reveals molecular determinants of intrinsic physiological properties. Neuron. 2019;103:598–616 e597.

[63] Mo K, Wu S, Gu X, et al. MBD1 contributes to the genesis of acute pain and neuropathic pain by epigenetic silencing of Oprm1 and Kcn2 genes in primary sensory neurons. J Neurosci. 2018;38:9883–9899.

[64] Kurihara M, Kato K, Sanbo C, et al. Genomic profiling by ALaP-Seq reveals transcriptional regulation by PML bodies through DNMT3A exclusion. Mol Cell. 2020;78:493–505 e498.

[65] Aneichyk T, Hendriks WT, Yadav R, et al. Dissecting the causal mechanism of X-linked dystonia-parkinsonism by integrating genome and transcriptome assembly. Cell. 2018;172:897–909 e821.

[66] Bautista DM. Spicy science: David Julius and the discovery of temperature-sensitive TRP channels. Temperature (Austin). 2015;2:135–141.

[67] Gu T, Lin X, Cullen SM, et al. DNMT3A and TET1 cooperate to regulate promoter epigenetic landscapes in mouse embryonic stem cells. Genome Biol. 2018;19:88.

[68] Marina RJ, Sturgill D, Bailly MA, et al. TET-catalyzed oxidation of intragenic 5-methylcytosine regulates CTCF-dependent alternative splicing. Embo J. 2016;35:335–355.

[69] d’Ydewalle C, Ramos DM, Pyles NJ, et al. The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron. 2017;93:66–79.

[70] Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24:1634–1644.

[71] Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3:72ra18.

[72] Singh NK, Singh NN, Androphy EJ, et al. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. 2006;26:1333–1346.

[73] Gapinske M, Luu A, Winter J, et al. CRISPR-SKIP: programmable generic splicing with single base editors. Genome Biol. 2018;19:107.

[74] Konermann S, Lotfy P, Brideau NJ, et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell. 2018;173:665–676 e614.

[75] Yuan J, Ma Y, Huang T, et al. Genetic modulation of RNA splicing with a CRISPR-guided cytidine deaminase. Mol Cell. 2018;72:380–394 e387.

[76] Liu XS, Jaenisch R. Editing the epigenome to tackle brain disorders. Trends Neurosci. 2019;42:861–870.